To obtain a comprehensive list of potential DYRK2 targets, we treated the myeloma U266 cells with C17 and carried out quantitative phosphoproteomic analyses (Chen et al., 2018; Hogrebe et al., 2018). This evidence concerns the gene DYRK2 and plasma cell myeloma.